Shikiar Asset Management Inc. trimmed its holdings in shares of Humana Inc. (NYSE:HUM – Get Rating) by 70.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 995 shares of the insurance provider’s stock after selling 2,360 shares during the period. Shikiar Asset Management Inc.’s holdings in Humana were worth $433,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Moors & Cabot Inc. boosted its position in Humana by 1.7% during the third quarter. Moors & Cabot Inc. now owns 1,455 shares of the insurance provider’s stock valued at $567,000 after buying an additional 24 shares during the period. Glassman Wealth Services boosted its holdings in shares of Humana by 10.5% during the fourth quarter. Glassman Wealth Services now owns 252 shares of the insurance provider’s stock worth $117,000 after purchasing an additional 24 shares during the period. B. Riley Wealth Management Inc. raised its stake in Humana by 5.0% in the fourth quarter. B. Riley Wealth Management Inc. now owns 546 shares of the insurance provider’s stock worth $253,000 after buying an additional 26 shares in the last quarter. Cribstone Capital Management LLC raised its stake in Humana by 2.3% in the third quarter. Cribstone Capital Management LLC now owns 1,263 shares of the insurance provider’s stock worth $491,000 after buying an additional 28 shares in the last quarter. Finally, Johnson Financial Group Inc. raised its stake in Humana by 12.7% in the fourth quarter. Johnson Financial Group Inc. now owns 258 shares of the insurance provider’s stock worth $120,000 after buying an additional 29 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.
In related news, CAO William Kevin Fleming sold 3,210 shares of the firm’s stock in a transaction that occurred on Thursday, April 28th. The shares were sold at an average price of $449.68, for a total value of $1,443,472.80. Following the sale, the chief accounting officer now owns 884 shares in the company, valued at $397,517.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Samir Deshpande sold 3,957 shares of the firm’s stock in a transaction that occurred on Tuesday, May 3rd. The stock was sold at an average price of $434.19, for a total transaction of $1,718,089.83. Following the completion of the sale, the insider now owns 5,529 shares in the company, valued at approximately $2,400,636.51. The disclosure for this sale can be found here. Insiders have sold 10,644 shares of company stock valued at $4,702,360 in the last three months. 0.39% of the stock is owned by insiders.
Humana (NYSE:HUM – Get Rating) last announced its quarterly earnings results on Wednesday, April 27th. The insurance provider reported $8.04 earnings per share for the quarter, beating the consensus estimate of $6.83 by $1.21. The company had revenue of $23.97 billion during the quarter, compared to the consensus estimate of $23.54 billion. Humana had a net margin of 3.51% and a return on equity of 17.27%. The firm’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same quarter last year, the firm earned $7.67 earnings per share. On average, sell-side analysts expect that Humana Inc. will post 24.65 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Thursday, June 30th will be given a dividend of $0.7875 per share. This represents a $3.15 annualized dividend and a dividend yield of 0.70%. The ex-dividend date of this dividend is Wednesday, June 29th. Humana’s dividend payout ratio (DPR) is currently 13.36%.
A number of equities analysts recently issued reports on HUM shares. Wells Fargo & Company increased their price target on shares of Humana from $512.00 to $514.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 25th. Loop Capital started coverage on shares of Humana in a research note on Thursday, June 16th. They issued a “buy” rating and a $510.00 price target for the company. Morgan Stanley increased their price target on shares of Humana from $410.00 to $436.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 9th. Truist Financial increased their price target on shares of Humana from $460.00 to $490.00 in a research note on Thursday, April 7th. Finally, Sanford C. Bernstein began coverage on shares of Humana in a research note on Thursday, May 26th. They issued a “market perform” rating and a $506.00 price target for the company. Seven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $493.38.
Humana Company Profile (Get Rating)
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Get a free copy of the StockNews.com research report on Humana (HUM)
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.